Target Information

Target General Infomation
Target ID
T34599
Former ID
TTDI01913
Target Name
Bacterial penicillin binding protein
Target Type
Successful
Disease Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10: A00-B99]
Bacterial respiratory tract infection [ICD10: J13, J15]
Intensive care unit; Bacterial infections [ICD9: 001-009, 001-139, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10: A00-B99]
Unspecified [ICD code not available]
Function
Cell wall formation.
Drugs and Mode of Action
Drug(s) Carbenicillin Indanyl Sodium Drug Info Approved Bacterial infections [551871]
Ceftriaxone Drug Info Approved Bacterial infections [536773], [540769]
Cephaloglycin Drug Info Approved Bacterial infections [550677]
Cephalothin Sodium Drug Info Approved Bacterial infections [551871]
Hetacillin Drug Info Approved Bacterial infections [551871]
Meropenem Drug Info Approved Bacterial infections [536361]
Penicillin Drug Info Approved Bacterial infections [521871]
Penicillin G Benzathine Drug Info Approved Bacterial infections [551871]
Penicillin G Procaine Drug Info Approved Bacterial infections [551871]
Penicillin G Sodium Drug Info Approved Bacterial infections [551871]
Penicillin V Potassium Drug Info Approved Bacterial infections [551871]
Ceftolozane sulfate Drug Info Phase 4 Bacterial respiratory tract infection [525160]
Cefluprenam Drug Info Phase 3 Bacterial infections [534476]
Lenapenem hydrochloride hydrate Drug Info Phase 2 Bacterial infections [545141]
Sulopenem Drug Info Phase 2 Unspecified [537981]
BAL-30072 Drug Info Phase 1 Bacterial infections [549110]
Ceftobiprole Drug Info Phase 1 Intensive care unit; Bacterial infections [536773]
DZ-2640 Drug Info Phase 1 Bacterial infections [525696]
Hetacillin Drug Info Withdrawn from market Bacterial infections [550713]
CEFCANEL DALOXATE HYDROCHLORIDE Drug Info Discontinued in Phase 3 Bacterial infections [545259]
CEFETECOL Drug Info Discontinued in Phase 3 Bacterial infections [544663]
Sanfetrinem Drug Info Discontinued in Phase 3 Bacterial infections [545093]
KP-736 Drug Info Discontinued in Phase 2 Bacterial infections [544662]
PA-1806 Drug Info Discontinued in Phase 2 Bacterial infections [546907]
Tomopenem Drug Info Discontinued in Phase 2 Bacterial infections [547270]
BRL-44154 Drug Info Discontinued in Phase 1 Bacterial infections [545915]
CEFDALOXIME PENTEXIL TOSILATE Drug Info Discontinued in Phase 1 Bacterial infections [545625]
CEFTRAZONAL BOPENTIL Drug Info Discontinued in Phase 1 Bacterial infections [545318]
DU-6681 Drug Info Discontinued in Phase 1 Bacterial infections [546080]
ER-35786 Drug Info Discontinued in Phase 1 Bacterial infections [546021]
FK-041 Drug Info Discontinued in Phase 1 Bacterial infections [546348]
MC-02,479 Drug Info Discontinued in Phase 1 Bacterial infections [546636]
BK-218 Drug Info Terminated Bacterial infections [544659]
Inhibitor BAL-30072 Drug Info [530802]
BK-218 Drug Info [531273]
Cefluprenam Drug Info [529176]
CEFTRAZONAL BOPENTIL Drug Info [526962]
ER-35786 Drug Info [534319]
FK-041 Drug Info [525603]
Lenapenem hydrochloride hydrate Drug Info [534358]
MC-02,479 Drug Info [526523]
Modulator BRL-44154 Drug Info [550042]
Carbenicillin Indanyl Sodium Drug Info
CEFCANEL DALOXATE HYDROCHLORIDE Drug Info [533920]
CEFDALOXIME PENTEXIL TOSILATE Drug Info [528201]
CEFETECOL Drug Info [530718]
Ceftobiprole Drug Info [552696]
Ceftolozane sulfate Drug Info [1572591]
Ceftriaxone Drug Info [556264]
Cephaloglycin Drug Info [556264]
Cephalothin Sodium Drug Info [556264]
DU-6681 Drug Info [544492]
DZ-2640 Drug Info [525819]
Hetacillin Drug Info
KP-736 Drug Info [530714]
Meropenem Drug Info [556264]
PA-1806 Drug Info
Penicillin Drug Info
Penicillin G Benzathine Drug Info
Penicillin G Procaine Drug Info
Penicillin G Sodium Drug Info
Penicillin V Potassium Drug Info [556264]
RO 244383 Drug Info
Sanfetrinem Drug Info
Sanfetrinem cilexetil Drug Info
Sulopenem Drug Info [537981]
Tomopenem Drug Info
References
Ref 521871ClinicalTrials.gov (NCT00363688) Treating Patients With a History of Non-Life Threatening Allergic Reaction to Penicillin With Penicillin. U.S. National Institutes of Health.
Ref 525160ClinicalTrials.gov (NCT02421120) Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients. U.S. National Institutes of Health.
Ref 525696Pharmacokinetics and safety of ascending single doses of DZ-2640, a new oral carbapenem antibiotic, administered to healthy Japanese subjects. Antimicrob Agents Chemother. 2000 Mar;44(3):578-82.
Ref 534476Usefulness of 7 day therapy with cefluprenam in the management of respiratory tract infections. Kansenshogaku Zasshi. 1997 Aug;71(8):770-87.
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 536773How many modes of action should an antibiotic have? Curr Opin Pharmacol. 2008 Oct;8(5):564-73. Epub 2008 Jul 30.
Ref 537981In vitro antibacterial activity of a new parenteral penem, sulopenem. Jpn J Antibiot. 1996 Apr;49(4):324-37.
Ref 540769(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5326).
Ref 544659Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000460)
Ref 544662Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000467)
Ref 544663Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000482)
Ref 545093Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002101)
Ref 545141Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002282)
Ref 545259Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002619)
Ref 545318Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002807)
Ref 545625Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003956)
Ref 545915Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005339)
Ref 546021Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005932)
Ref 546080Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006219)
Ref 546348Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007635)
Ref 546636Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009332)
Ref 546907Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011023)
Ref 547270Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014654)
Ref 549110Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032341)
Ref 550677Drug information of Cephaloglycin, 2008. eduDrugs.
Ref 550713Drug information of Hetacillin, 2008. eduDrugs.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref
Ref 525603In vitro antibacterial activity of FK041, a new orally active cephalosporin. J Antibiot (Tokyo). 1999 Jul;52(7):649-59.
Ref 525819In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins. J Antimicrob Chemother. 2000 Jul;46(1):101-8.
Ref 526523Antimicrob Agents Chemother. 2003 Feb;47(2):658-64.RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal beta-lactamases.
Ref 526962Comparative in vitro activity of Ro 40-6890, Ro 41-3399, and other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 1992 Oct;11(10):946-9.
Ref 528201Activity of cefpodoxime and other oral beta-lactams against Haemophilus influenzae and Streptococcus pneumoniae with different susceptibilities to penicillin. Rev Esp Quimioter. 2006 Mar;19(1):39-44.
Ref 529176Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother. 1991 Nov;35(11):2312-7.
Ref 530714In vitro antibacterial activity of KP-736, a new cephem antibiotic. Antimicrob Agents Chemother. 1991 Jan;35(1):104-10.
Ref 530718Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1991 Jan;35(1):14-9.
Ref 530802In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother. 2010 Jun;54(6):2291-302.
Ref 531273In vitro investigation of BK-218, a new oral and parenteral cephalosporin. Antimicrob Agents Chemother. 1990 Feb;34(2):349-54.
Ref 533920Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function. J Antimicrob Chemother. 1994 Feb;33(2):281-8.
Ref 534319In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. Antimicrob Agents Chemother. 1997 Feb;41(2):298-307.
Ref 534358Affinities of BO-2727 for bacterial penicillin-binding proteins and morphological change of gram-negative rods. J Antibiot (Tokyo). 1997 Feb;50(2):139-42.
Ref 537981In vitro antibacterial activity of a new parenteral penem, sulopenem. Jpn J Antibiot. 1996 Apr;49(4):324-37.
Ref 544492Pharmacokinetics and Safety of Ascending Single Doses of DZ-2640, a New Oral Carbapenem Antibiotic, Administered to Healthy Japanese Subjects. Antimicrob Agents Chemother. 2000 March; 44(3): 578-582.
Ref 550042Can beta-lactams be re-engineered to beat MRSA?. Clinical Microbiology and Infection Volume 12, Issue Supplement s2, pages 11-16, April 2006.
Ref 552696Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2007 Jul;51(7):2621-4. Epub 2007 Apr 30.
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.